SRTD Biotech, a German company developing mRNA medicines designed to work only in diseased cells, raised €31.5m (about $36.2m) in a seed round, it announced on 9 November 2026.
Mérieux Equity Partners led the round through its Mérieux Innovation 2 fund. NRW.BANK, through its NRW.Venture EU Tech&Scale fund, and the Boehringer Ingelheim Venture Fund co-led. Lilly Ventures, High-Tech Gründerfonds and Anobis Asset, a family office in Freiburg, also invested. The company said the round was oversubscribed, and called it one of the largest biotech seed rounds in Europe. No valuation was disclosed.
“SRTD Biotech shows how cutting-edge research from North Rhine-Westphalia can open up new ways to treat many diseases with significant unmet medical needs. Bringing innovations like these from research into medical practice takes capital.”Johanna Antonie Tjaden-Schulte, Member of the Managing Board, NRW.BANK
What SRTD Biotech does
mRNA medicines tell cells to make a protein. A problem for many potential treatments is that the mRNA also reaches healthy cells, which can cause side effects. SRTD's seRNA platform, short for selectively expressed RNA, uses RNA markers found inside diseased cells as a switch, so the mRNA produces its protein only in the cells it is meant to target.
The company also has a delivery platform based on fusogenic lipid nanoparticles, fatty particles designed to carry the mRNA to the liver, lung, brain and other organs. A third platform uses synthetic biology, bioinformatics and AI to design the RNA.
Its pipeline of targeted RNA treatments covers cancer, autoimmune diseases and fibrosis, all at the preclinical stage.
The company says the approach is meant to overcome two limits of current mRNA and targeted drugs: mRNA that is expressed in every cell it reaches, and the reliance on proteins on the surface of cells to find the right target. It describes itself as an integrated company that can take RNA medicines from design to delivery across many diseases.
The team
SRTD was founded in 2019 by Dr Bernd Hoffmann, its chief scientific officer. With the round the company appointed Matthias Alder as chief executive. He has been chief executive, chief operating officer and chief business officer at listed biotech companies in the US and Europe.
Dr Heinz Koeppl, chief technology officer, founded the synthetic biology platform and directs the Centre for Synthetic Biology at TU Darmstadt. He will lead scientific strategy together with Hoffmann. Dr Jens Hennecke joins as chief business officer to handle partnerships.
EU-Startups named Dr Heribert Bohlen as a co-founder alongside Hoffmann. Alder said the money will let SRTD advance Hoffmann's vision of safe, effective RNA medicines for patients whose diseases are not well served by current treatments.
What the money is for
SRTD said the money will take its pipeline through preclinical development towards an Investigational New Drug application, the filing needed to start clinical trials in the US. It also plans research collaborations with other companies beyond its own drug candidates.
Kristin Thompson, a director at Mérieux Equity Partners, said the firm believes SRTD has the potential to redefine what is possible with mRNA medicines. Alder thanked the investors for joining what he called an exceptional syndicate.
Thompson said Mérieux had worked closely with the company to strengthen its strategy, build its leadership team and set up a platform that can scale before leading the round. NRW.BANK's Johanna Antonie Tjaden-Schulte said the investment helps a company develop a new technology in North Rhine-Westphalia and grow it internationally from there.
Company website: srtd-biotech.com
